The M∙A∙C AIDS Fund, Rihanna and UNAIDS team up to reach nearly 2 million young people in need of lifesaving HIV treatment

Star studded effort to support the expansion of Treatment 2015 with US$ 2 million grant to UNAIDS to deliver HIV treatment and care for adolescents and young people worldwide

GENEVA/NEW YORK, 30 January 2014-The Joint United Nations Programme on HIV/AIDS (UNAIDS) announced today the expansion of its Treatment 2015 initiative with a US$ 2 million grant provided by the heart and soul of M∙A∙C Cosmetics, the M∙A∙C AIDS Fund. The Fund is fully supported from the sale of VIVA GLAM Lipstick and Lipglass with global superstar Rihanna lending her celebrity to spur purchase and awareness. Leveraging this new funding, UNAIDS will build on Treatment 2015 by advancing global, regional and country level policies and programs to expand HIV testing and treatment to young people worldwide.

“M∙A∙C Cosmetics has a long history of engaging the right star power to motivate our customers and make an impact on this important cause. With UNAIDS’ resources and strategic thinking and Rihanna’s passionate support, we’re helping save lives one lipstick at a time,” said John Demsey, Group President of The EstŽe Lauder Companies.

Globally, an estimated 5.4 million[1] adolescents and young people are living with HIV, and 1.8 million[1] are eligible for HIV treatment. Millions of young people living with HIV do not know they are infected, and every day, approximately 2,100 adolescents and young people[1] are newly infected, which accounts for 39% of all new HIV infections globally. While antiretroviral therapy has resulted in a decline in AIDS-related deaths, modelling suggests that adolescents from 10 to 19-years-old are the only age group in which AIDS-related deaths rose between 2001 and 2012. The trend in AIDS-related deaths can be attributed to poor prioritization of adolescents in strategic plans for scale-up of HIV treatment and the lack of testing and counselling.

“Young people will lead us to an AIDS-free generation. By ensuring adolescents and young people have access to HIV services, we are not only saving lives but also investing in a healthier future for generations to come,” said Michel SidibŽ, Executive Director of UNAIDS. “We are truly honored to be working with the M∙A∙C AIDS Fund to help young people around the world access earlier HIV testing and treatment.”

UNAIDS
Read More

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below

Laboratory Order Forms

Start typing and press enter to search